Literature DB >> 1702157

Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

N Kniess1, M Mach, J Fay, W J Britt.   

Abstract

Human convalescent serum and bacterial fusion proteins constructed from overlapping open reading frames of the nucleotide sequence encoding the human cytomegalovirus gp55 component of the major envelope glycoprotein complex, gp55-116 (gB), were used to localize antigenic regions recognized by human antibodies. All donor serum analyzed contained antibody reactivity for an antigenic site(s) located between amino acids (AA) 589 and 645, a region containing a previously defined linear site recognized by neutralizing monoclonal antibodies (U. Utz, B. Britt, L. Vugler, and M. Mach, J. Virol. 63:1995-2001, 1989). Furthermore, in-frame insertion of two different synthetic oligonucleotides encoding four amino acids into the sequence at nucleotide 1847 (AA 616) eliminated antibody recognition of the fusion protein. A second antibody binding site was located within the carboxyl terminus of the protein (AA 703 through 906). A competitive binding inhibition assay in which monoclonal antibodies were used to inhibit human antibody reactivity with recombinant gp55-116 (gB) suggested that the majority of human anti-gp55-116 (gB) antibodies were directed against a single antigenic region located between AA 589 and 645. Furthermore, inoculation of mice with fusion proteins containing this antigenic site led to a boostable antibody response. These results indicated that the antigenic site(s) located between AA 589 and 645 was an immunodominant antibody recognition site on gp55 and likely the whole gp55-116 (gB) molecule. The enhanced immunogenicity of this region in vivo may account for its immunodominance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702157      PMCID: PMC240498     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Antibodies that react with predetermined sites on proteins.

Authors:  J G Sutcliffe; T M Shinnick; N Green; R A Lerner
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

2.  Immunogenic structure of the influenza virus hemagglutinin.

Authors:  N Green; H Alexander; A Olson; S Alexander; T M Shinnick; J G Sutcliffe; R A Lerner
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

Review 3.  Selection of particles and proteins for use as human cytomegalovirus subunit vaccines.

Authors:  W Gibson; A Irmiere
Journal:  Birth Defects Orig Artic Ser       Date:  1984

4.  Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.

Authors:  E A Emini; B A Jameson; E Wimmer
Journal:  Nature       Date:  1983 Aug 25-31       Impact factor: 49.962

5.  Mapping of 10 epitopes on bovine herpesvirus type 1 glycoproteins gI and gIII.

Authors:  D R Fitzpatrick; M J Redmond; S K Attah-Poku; S van Drunen Littel-van den Hurk; L A Babiuk; T J Zamb
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

6.  Pseudorabies virus glycoprotein gI: in vitro and in vivo analysis of immunorelevant epitopes.

Authors:  W Fuchs; H J Rziha; N Lukàcs; I Braunschweiger; N Visser; D Lütticken; C S Schreurs; H J Thiel; T C Mettenleiter
Journal:  J Gen Virol       Date:  1990-05       Impact factor: 3.891

7.  Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne.

Authors:  R R Spaete; A Saxena; P I Scott; G J Song; W S Probert; W J Britt; W Gibson; L Rasmussen; C Pachl
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

8.  Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections.

Authors:  W J Britt; L G Vugler
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

9.  Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells.

Authors:  D E Wells; L G Vugler; W J Britt
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

10.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.

Authors:  W J Britt; L Vugler; E J Butfiloski; E B Stephens
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

View more
  27 in total

1.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116).

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Comparison of rapid methods of detection of cytomegalovirus in saliva with virus isolation in tissue culture.

Authors:  W P Warren; K Balcarek; R Smith; R F Pass
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

4.  Sustained expression of human cytomegalovirus glycoprotein B (UL55) in the seeds of homozygous rice plants.

Authors:  Eilleen S Tackaberry; Fiona A Prior; Karen Rowlandson; Monika Tocchi; Jelica Mehic; Suzanne Porter; Mike Walsh; Mark R Schleiss; Peter R Ganz; Ravinder K Sardana; Illimar Altosaar; Anil K Dudani
Journal:  Mol Biotechnol       Date:  2008-04-16       Impact factor: 2.695

5.  Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites.

Authors:  J A Simpson; J C Chow; J Baker; N Avdalovic; S Yuan; D Au; M S Co; M Vasquez; W J Britt; K L Coelingh
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

6.  Human cytomegalovirus glycoprotein B contains autonomous determinants for vectorial targeting to apical membranes of polarized epithelial cells.

Authors:  S Tugizov; E Maidji; J Xiao; Z Zheng; L Pereira
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

Authors:  M Ohlin; M Silvestri; V A Sundqvist; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

8.  Comparative sequence analysis of human cytomegalovirus strains.

Authors:  R Lehner; T Stamminger; M Mach
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

9.  Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding.

Authors:  M A Billstrom; W J Britt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.